Adrenocortical Carcinoma Treatment Market with Asia Pacific as the Major Growth-oriented Region – Coherent Market Insights
Adrenocortical Carcinoma Treatment Market report provides key enumeration on the Market status of the Adrenocortical Carcinoma Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Adrenocortical Carcinoma Treatment industry. It delivers important information to identify and analyse the market need, market Growth and competition.
The global Adrenocortical Carcinoma Treatment Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Adrenocortical Carcinoma Treatment Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Adrenocortical carcinoma is an uncommon cancer that affects the outer layer of the adrenal glands, which are in charge of generating hormones and keeping blood pressure at a healthy level. In comparison to other malignancies, adrenocortical carcinoma is more common in youngsters, however, it can also afflict adults. Stomach discomfort, pressure, excess weight, and increased urination are the most typical symptoms of adrenocortical carcinoma, which are caused by tumors that induce excessive hormone production from the adrenal glands. Mitotane is the only medication authorized for the treatment of metastatic adrenocortical carcinoma by the U.S. FDA (Food and Drug Administration) and the EMEA (European Medicines Agency).
A significant factor driving the growth of the global adrenocortical carcinoma treatment market is the rising prevalence of adrenocortical carcinoma linked to genetic abnormalities. According to the Journal of Clinical Endocrinology & Metabolism, the peak incidence of adrenocortical carcinoma occurs between the ages of 40 and 50, with women being 55–60 percent more probable than males.
Furthermore, numerous organizations and businesses are conducting more clinical trials for various chemotherapeutics. ATR-101 was first tested in a Phase 1 study in 2013 by Millendo Therapeutics, Inc. for the treatment of adrenocortical cancer. A Phase II study of Cisplatin and sodium thiosulfate for surgical removal and HIPEC (Heated Intraperitoneal Peritoneal Chemotherapy) for adrenocortical cancer was also launched by the National Cancer Institute.
Due to the rising incidence of the disease and the presence of major players focused on developing novel products, North America is projected to attain a leading position in the global adrenocortical carcinoma treatment market during the forecast period, trailed by Europe. According to the National Institutes of Health’s Office of Rare Diseases Research, there are around 600 new instances of adrenal cancer diagnosed each year in the U.S. Furthermore, institutions like the University of Michigan Rogel Cancer Center are working on stem cell research to improve adrenal cancer treatment.
Due to the greater prevalence rates of the disease in Brazil, Latin America is projected to acquire substantial traction during the forecast period. According to the ACC C.U.R.E. Organization’s report, adrenal cancer is 15 times more common in Brazil than in any other country, owing to a high incidence of a single gene mutation, TP53. According to the Endocrine Society, Brazil’s childhood incidence ranges from 2.9 to 4.2 per million per year, compared to an estimated global incidence of 0.2 to 0.3 per million children per year.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1551
Reasons to Purchase this Report
• Current and future of global Adrenocortical Carcinoma Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Adrenocortical Carcinoma Treatment Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of ArQule, Inc., EnGeneIC Ltd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and Orphagen Pharmaceuticals, Inc.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire